Two Sigma Investments LP Has $130,000 Holdings in Alto Neuroscience, Inc. (NYSE:ANRO)

Two Sigma Investments LP grew its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 137.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,700 shares of the company’s stock after buying an additional 17,760 shares during the period. Two Sigma Investments LP owned approximately 0.11% of Alto Neuroscience worth $130,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Point72 Asset Management L.P. lifted its position in shares of Alto Neuroscience by 73.1% during the 4th quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company’s stock valued at $7,158,000 after acquiring an additional 714,461 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Alto Neuroscience by 4.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 844,823 shares of the company’s stock worth $3,575,000 after purchasing an additional 36,319 shares during the period. Marshall Wace LLP bought a new stake in Alto Neuroscience in the fourth quarter valued at $3,542,000. Northern Trust Corp raised its holdings in shares of Alto Neuroscience by 198.1% during the fourth quarter. Northern Trust Corp now owns 587,135 shares of the company’s stock valued at $2,484,000 after purchasing an additional 390,190 shares during the period. Finally, Cantor Fitzgerald L. P. acquired a new position in shares of Alto Neuroscience during the fourth quarter valued at about $1,575,000.

Analyst Ratings Changes

ANRO has been the subject of several research reports. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Wedbush reiterated a “neutral” rating and issued a $4.00 price target on shares of Alto Neuroscience in a report on Thursday, May 15th. Finally, HC Wainwright started coverage on Alto Neuroscience in a research note on Monday, April 7th. They issued a “buy” rating and a $10.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and an average price target of $15.40.

Alto Neuroscience Trading Down 2.0%

NYSE:ANRO opened at $2.45 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. Alto Neuroscience, Inc. has a one year low of $1.60 and a one year high of $17.55. The company has a market cap of $66.33 million, a PE ratio of -1.05 and a beta of 1.93. The firm has a 50-day moving average of $2.42 and a 200-day moving average of $3.23.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.06. As a group, equities research analysts expect that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.